# Bacterial or viral?

LIAISON® MeMed BV®

The new test enables physicians to accurately differentiate between bacterial and viral infections, thus supporting fast and more-informed treatment and patient management decisions

This pioneering solution is now available on the DiaSorin **LIAISON® XL** analyzer

DiaSorin
The Diagnostic Specialist

MeMed

LIAISON® MeMed BV®

The easy, high-quality way to enhance clinical decision-making while fighting the problem of antimicrobial resistance

LIAISON® MeMed BV® delivers fast diagnostic differentiation between bacterial and viral infections in a single procedure, helping transform the treatment of infectious diseases.

Is the infection bacterial or viral?

To treat or not to treat with antibiotics?

# Accurately distinguishes between bacterial and viral infections

DiaSorin's newest high-throughput, high-quality chemiluminescent

assay easily identifies the source of a patient's infection using the

LIAISON® XL automatic analyzer.

Bacterial or viral:

Since bacterial and viral infections are clinically indistinguishable, physicians are often challenged when deciding whether or not to treat an illness with antibiotics. LIAISON® MeMed BV® provides host immune response information, helping physicians make more informed treatment decisions.

# Antibiotics are the most misused drugs:

50%

Antibiotic overuse [1-4]

20%

Antibiotic underuse [5-7]

Conventional tests are often insufficient...

Multi-step workflow required

Prolonged time to results

Risk of antibiotic misuse

Limited sensitivity and specificity

Uncertainty regarding severity

Lack of automated testing procedures

Three biomarkers + machine learning = better patient care

From a simple serological sample, **LIAISON® MeMed BV®** automatically measures, analyzes and integrates the levels of three host immune proteins into a single and simple score, showing the likelihood of a bacterial immune response or co-infection versus a likely viral immune response.

The computational signature for accurate diagnosis of acute bacterial (or mixed) versus viral infections was developed and validated on >20,000 cohort of patients. [8-12]

10 < score <35
Moderate likelihood of viral infection
(or other non-bacterial etiology)

65 < score < 90
Moderate likelihood of bacterial infection
(or co-infection)

V
(Viral/Other)

B
(Bacterial)

0 ≤ score ≤10
High likelihood of viral infection
(or other non-bacterial etiology)

35 ≤ score ≤ 65
Equivocal

90 ≤ score ≤ 100
High likelihood of bacterial infection
(or co-infection)

The numeric score falls within discrete interpretation ranges based on the increasing likelihood of bacterial infection

The clinical performances of **LIAISON® MeMed BV®** has been confirmed in validation based on testing with patients with signs and symptoms suggestive of acute bacterial or viral infection. Measures of Sensitivity, Specificity and Negative Predictive Value (NPV) have been calculated by considering a bacterial result as positive and a viral/other result as negative.

Performances*

96.3%

Sensitivity

91.3%

Specificity

99.5%

NPV

*Data based on secondary endpoint analysis

Accurate results in less than 1 hour

Pairing powerful yet simple chemiluminescence immunoassay (CLIA) analysis with high sensitivity and precision, DiaSorin fully supports clinical decision making by delivering reliable and easy-to-interpret scientific data in less than 1 hour. Put your trust in our value-based care solution and benefit from the speed and precision of DiaSorin diagnostic excellence.

LIAISON® MeMed BV® – empowering patient care while fighting the problem of antimicrobial resistance.

REQUEST INFORMATION

References:

1. Davey P et al.; Emerg Infect Dis. 2006
2. Linder JA et al.; JAMA. 2001
3. 3Cadieux G et al.; CMAJ. 2007
4. Pulcini C et al.; Eur J Clin Microbiol Infect Dis. 2007
5. Battleman DS et al.; Arch Intern Med. 2002
6. Houck PM et al.; Arch Intern Med.
7. Craig JC et al.; BMJ. 2010
8. Oved K et al.; PLoS One. 2015
9. van Houten CB et al.; Lancet Infect Dis. 2017
10. Srugo I et al.; Pediatrics. 2017
11. Ashkenazi-Hoffnung L et al.; Eur J Clin Microbiol Infect Dis. 2018
12. Stein M et al.; Diagn Microbiol Infect Dis. 2018

Product availability subject to required regulatory approval

DiaSorin
The Diagnostic Specialist

DiaSorin S.p.A.
Via Crescentino SNC, 13040 Saluggia (VC) - Italy
www.diasorin.com

MeMed

M0870004421/A 03/22